SEARCH

SEARCH BY CITATION

References

  • 1
    Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. American Journal of Medicine. 2009; 122 (Suppl-13).
  • 2
    Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. New England Journal of Medicine. 2007; 357: 905916.
  • 3
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis [see comment]. New England Journal of Medicine. 2001; 344: 14341441.
  • 4
    Seeman E, Compston J, Adachi J, et al. Non-compliance: the achilles heel of anti-fracture efficacy. Osteoporosis International. 2007; 18: 711719.
  • 5
    Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin d and dose dependency a meta-analysis of randomized controlled trials. Archives of Internal Medicine. 2009; 169: 551561.
  • 6
    Orimo H, Shiraki M, Hayashi Y, et al. Effects of 1α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcified Tissue International. 1994; 54: 370376.
  • 7
    Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. New England Journal of Medicine. 1992; 327: 16371642.
  • 8
    DeLuca HF. Overview of general physiologic features and functions of vitamin D. American Journal of Clinical Nutrition. 2004; 80 (Suppl-96S).
  • 9
    Chen JT, Shiraki M, Hasumi K, et al. 1-α-Hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone. 1997; 20: 557562.
  • 10
    Matsumoto T, Miki T, Hagino H, et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. Journal of Clinical Endocrinology & Metabolism. 2005; 90: 50315036.
  • 11
    Bouillon R, Van CS, Carmeliet G. Intestinal calcium absorption: Molecular vitamin D–mediated mechanisms. Journal of Cellular Biochemistry. 2003; 88: 332339.
  • 12
    Bouillon R, Verlinden L, Eelen G, De CP, Vandewalle M, Mathieu C, Verstuyf A. Mechanisms for the selective action of Vitamin D analogues. Journal of Steroid Biochemistry & Molecular Biology. 2005; 97: 2130.
  • 13
    Bikle D. Nonclassic actions of vitamin D. Journal of Clinical Endocrinology & Metabolism. 2009; 94: 2634.
  • 14
    Erben Reinhold G, Scutt Andrew M, Miao D, Kollenkirchen U, Haberey M. Short-term treatment of rats with high dose 1,25-dihydroxyvitamin D3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology. 1997; 138: 46294635.
  • 15
    Erben Reinhold G, Bromm S, Stangassinger M. Therapeutic efficacy of 1α,25-dihydroxyvitamin D3 and calcium in osteopenic ovariectomized rats: evidence for a direct anabolic effect of 1α,25-dihydroxyvitamin D3 on bone. Endocrinology. 1998; 139: 43194328.
  • 16
    Shiraishi A, Takeda S, Masaki T, et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. Journal of Bone & Mineral Research. 2000; 15: 770779.
  • 17
    Uchiyama Y, Higuchi Y, Takeda S, et al. ED-71, a vitamin D analogue, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone. 2002; 30: 582588.
  • 18
    Khanal RC, Nemere I. Regulation of intestinal calcium transport. Annual Review of Nutrition. 2008; 28: 179196.
  • 19
    Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D–mediated human antimicrobial response. Science. 2006; 311: 17701773.
  • 20
    Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006; 124: 823835.
  • 21
    Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Progress in Biophysics & Molecular Biology. 2006; 92: 6064.
  • 22
    Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmunity Reviews. 2006; 5: 114117.
  • 23
    Holick MF. Vitamin D: its role in cancer prevention and treatment. Progress in Biophysics & Molecular Biology. 2006; 92: 4959.
  • 24
    Spina CS, Ton L, Yao M, et al. Selective vitamin D receptor modulators and their effects on colorectal tumor growth. Journal of Steroid Biochemistry & Molecular Biology. 2007; 103: 757762.
  • 25
    Bischoff-Ferrari HA, Orav EJ, wson-Hughes B. Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Archives of Internal Medicine. 2006; 166: 424430.
  • 26
    Ma Y, Khalifa B, Yee YK, et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. Journal of Clinical Investigation. 2006; 116: 892904.
  • 27
    Dixon KM, Mason RS. Vitamin D. International Journal of Biochemistry & Cell Biology. 2009; 41: 982985.
  • 28
    Sato M, Zeng GQ, Turner CH. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology. 10/1997; 138: 43304337.
  • 29
    Burtis CA, Ashwood ER. Tietz Fundamentals of Clinical Chemistry. 5th Edition. In: SolbergHE, ed. Establishment and Use of Reference Values. International Federation of Clinical Chemistry, 2001: pp. 251261.
  • 30
    FDA, Food and Drug Administration 2004 Draft Guidance for Industry on the Preclinical and Clinical Evaluation of Agents used in the Prevention or Treatment of Postmenopausal Osteoporosis: Request for Comments., 69 ed., pp. 66736675.
  • 31
    European Medicines Agency 2005 Guideline on the Evaluation of New Medicinal Products in the Treatment of Osteoporosis.
  • 32
    Tsurukami H, Nakamura T, Suzuki K, Sato K, Higuchi Y, Nishii Y. A novel synthetic vitamin D analogue, 2β-(3-hydroxypropoxy)1α,25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcified Tissue International. 1994; 54: 142149.
  • 33
    Onyia JE, Helvering LM, Gelbert L, et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. Journal of Cellular Biochemistry. 2005; 95: 403418.